Our presentation from #ASGCT24 showing data on the use of Cas12a chRDNA for efficient genome editing in vivo is now available for viewing on our website: bit.ly/3wvWEhy
#CRISPR #geneediting

What was the inspiration behind Caribou’s HAAPI employee resource group? Lisa Latorre, associate director of quality assurance and HAAPI co-leader, explains what inspired her. #APAHM #AAPIMonth

In the past quarter, Caribou has announced an IND clearance for lupus and has made progress across our clinical pipeline of allogeneic CAR-T cell therapies. Read more about it in our first quarter 2024 financial results and business update: bit.ly/44zJgW4

#CRISPR $CRBU

Next week, our VP of medical affairs and project leadership Tonia Nesheiwat, PharmD, will participate in a panel discussion on strategies for building out a #medicalaffairs team during the FierceBiotech Medical Affairs Strategic Summit. Learn more: bit.ly/3xJWovu
#MASS

May is Asian American, Native Hawaiian, Pacific Islander Heritage Month – this month we are celebrating some of our amazing employees who contribute to our diverse and inclusive environment. Stay tuned to learn more about our HAAPI employee resource group and its members!
#APAHM

Mark your calendar for our presentations at upcoming investor conferences! Read our press release for more details: bit.ly/3y1mXg0
$CRBU

Today we announced two abstracts have been accepted at #ASCO24 . The event will feature an update on initial clinical data from dose expansion in ANTLER Phase 1 trial. Read today's release for more details: bit.ly/3UvNzON $CRBU #CellTherapy #CRISPR

Today is #AML AwarenessDay . Caribou Biosciences is committed to improving treatment for #AML by developing an off-the-shelf CAR-T cell therapy for this devastating disease. Learn more about CB-012 here:
bit.ly/3TKg3Eb
#leukemia #CRISPR #CARTcelltherapy

Ahead of #EarthDay , the Herd got together for our annual shoreline clean-up event, where our team picked up garbage and left the Berkeley shoreline better than we found it. #HerdImpact #LifeintheHerd

Going to #ASGCT24 ? Don’t miss our oral presentation featuring preclinical data on our in vivo genome editing platform. More details here: bit.ly/43XxJzQ
$CRBU #GeneEditing #CRISPR

The Caribou team had a great time at #AACR2024 . Thanks to everyone who stopped by the poster. If you missed it, be sure to check it out here: cariboubio.com/file.cfm/11/do…
#AACR24 #AML

Our poster presentation from #AACR2024 featuring preclinical, IND-enabling data from CB-012, our allogeneic anti-CLL-1 #CART cell therapy for the treatment of relapsed or refractory acute myeloid #leukemia , is now available for viewing on our website: bit.ly/49q55bG

Caribou Biosciences will host an investor call this afternoon at 5:00 pm ET/ 2:00 pm PT to discuss our expansion into autoimmune disease and the GALLOP Phase 1 study design. A link to the webcast is available on the investor section of our website: bit.ly/3E0bqxd $CRBU

$CRBU is expanding clinical development of CB-010 into #autoimmune disease . We have received IND clearance from the U.S. FDA for CB-010 in lupus nephritis and extrarenal lupus. More details on the GALLOP Phase 1 trial here: bit.ly/4am15dy #Lupus #autoimmune #CRISPR

Tomorrow at the H.C. Wainwright 2nd Annual Cell Therapy Conference, join $CRBU CEO Rachel Haurwitz, PhD, for a fireside chat at 11:30 am ET.
The webcast of the fireside chat can be found on our website here: bit.ly/3E0bqxd
#celltherapy #CRISPR

.@Cancerdotnet estimates 35,730 new cases of #MultipleMyeloma were diagnosed in 2023, and the 5-year survival rate is approximately 58%. Caribou is dedicated to improving the current standard of care with a novel cell therapy approach.
#MultipleMyeloma Awareness

Tune in today at 1:40 pm ET for a fireside chat with $CRBU CEO Rachel Haurwitz, PhD, at the Leerink Partners Global Biopharma Conference. A webcast of the event is available on the investor section of our website:
bit.ly/3E0bqxd
#celltherapy #CRISPR

2023 was a year of significant clinical progress for Caribou. We look forward to continuing this momentum in 2024.
Read our fourth quarter and full year 2023 financial results here: bit.ly/4a8SH0l
#celltherapy #CRISPR $CRBU